ASCPT CAREER CENTER
The best place to find qualified talent or career opportunities in the fields of clinical pharmacology and translational science.

POST YOUR JOB OR CURRICULUM VITAE TODAY!

WE HAVE HELPED HUNDREDS WORLDWIDE FILL JOB OPENINGS AND FIND THE PERFECT JOB ... AND WE CAN HELP YOU DO THE SAME.

www.ascpt.org/careercenter
A Strategy to Treat COVID-19 Disease with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Pre-clinical Pharmacokinetic Study

Tien-Tzu Tai¹, Tzung-Ju Wu², Huey-Dong Wu³, Yi-Chen Tsai², Hui-Ting Wang², An-Min Wang⁴, Sheue-Fang Shih⁵, Yee-Chun Chen⁶,#

¹Division of Corporate Development, Department of Regulatory Affairs, Taiwan Liposome Company, Ltd., Taipei, Taiwan
²Division of Product Development, Department of Pharmacokinetics, Taiwan Liposome Company, Ltd., Taipei, Taiwan
³Division of Respiratory Therapy, Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital, Taipei, Taiwan
⁴Division of Product Development, Department of Medical Science, Taiwan Liposome Company, Ltd., Taipei, Taiwan
⁵Division of Product Development, Taiwan Liposome Company, Ltd., Taipei, Taiwan
⁶Division of Infectious disease, Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan

#Corresponding author: Yee-Chun Chen
Department of Internal Medicine, National Taiwan University Hospital,
No. 7, Chung-Shan S Rd, Taipei, Taiwan 100
Phone: +886-2-2312-3456 #65054
Email: yeechunchen@gmail.com

This article is protected by copyright. All rights reserved
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly identified pathogen causing the coronavirus disease 2019 (COVID-19) pandemic. Hydroxychloroquine (HCQ), an antimalarial and anti-inflammatory drug, has been shown to inhibit SARS-CoV-2 infection in vitro and tested in clinical studies. However, achievement of lung concentrations predicted to have in vivo antiviral efficacy might not be possible with the currently proposed oral dosing regimens. Further, high cumulative doses of HCQ raise concerns of systemic toxicity, including cardiotoxicity. Here, we describe a pre-clinical study to investigate the pharmacokinetics of a novel formulation of liposomal HCQ administered by intratracheal (IT) instillation in Sprague-Dawley (SD) rats. Compared to unformulated HCQ administered intravenously (IV), liposomal HCQ showed higher (~30-fold) lung exposure, longer (~2.5-fold) half-life in lung, but lower blood exposure with ~20% of C_max and 74% of AUC_0-72 and lower heart exposure with 23% of C_max and 58% of AUC_0-24 (normalized for dose). Similar results were observed relative to IT administration of unformulated HCQ. These pharmacokinetics results in an animal model demonstrated the proof of concept that inhalable liposomal HCQ may provide clinical benefit and serve as a potential treatment for COVID-19.
**Introduction**

Hydroxychloroquine (HCQ), an antimalarial and anti-inflammatory drug, is inexpensive, safe, and well tolerated by most patient populations, including those with chronic diseases or immunocompromised status. HCQ is a weak diprotic base that can pass through the lipid cell membrane and preferentially be sequestered inside acidic cytoplasmic vesicles, such as lysosomes (lysosomotropic) \(^1\). HCQ has shown potential in against coronavirus disease 2019 (COVID-19) *in vitro* \(^2,3\) and is being studied in numerous clinical trials. As of Oct 16, 2020, there were a total of 258 studies involving HCQ use among 3611 clinical trials for COVID-19 registered on clinicaltrials.gov.

However, despite initial indications of HCQ effectiveness in smaller clinical studies \(^4,5\), the benefit of HCQ for COVID-19 patients has not been supported by large clinical trials \(^6,7\). One possible reason for the conflicting results is that the optimal dosing regimen of HCQ for treating COVID-19 remains unclear, and effective *in vivo* levels of HCQ may not be achievable. The *in vitro* EC\(_{50}\) values (0.72 to 17.31 µM) proposed for optimized dosing regimens are based on extracellular drug concentrations \(^2,3\). Modeling suggested that a higher lung (intracellular) concentration may be required for *in vivo* antiviral efficacy \(^8\). The HCQ concentration (6,700 ng/mL) required to clear 100% of SARS-CoV-2 *in vitro* might not be achievable in lung with the currently proposed oral dosing regimen of 800 mg HCQ sulfate orally daily, followed by a maintenance dose of 400 mg given daily for 4 days \(^3,9\). To achieve an effective antiviral HCQ concentration in lung, higher cumulative doses of HCQ would be required, raising concerns of systemic toxicity, including cardiotoxicity \(^10\).

An alternative strategy is needed to bridge the gap between *in vitro* and clinical use of a potentially effective agent in the context of COVID-19 pandemic. Drug delivery directly to the respiratory tracts while minimizing the systemic exposure may be a desirable alternative \(^8\).
proof-of-concept study, the pharmacokinetics (PK) of a novel inhalable liposomal HCQ were investigated in a rat model and compared to that of unformulated HCQ through intravenous (IV) or IT delivery.
Methods

Drugs and reagents. The study drug (liposomal HCQ) was prepared by the Taiwan Liposome Company (TLC), Ltd., Taiwan. The liposomes are composed of dipalmitoylphosphatidylcholine (Lipoid GMBH, Germany) and cholesterol (Carbogen Amcis B.V., The Netherlands). Hydroxychloroquine sulfate was obtained from SCI Pharmtech, Inc., Taiwan. The internal standard (primaquine diphosphate and hydroxychloroquine-d4 sulfate) was purchased from MedChemExpress, USA and Cayman, USA.

Study Design. A total of 52 female SD rats (BioLASCO Taiwan Co., Ltd.) were assigned to one of three treatment groups: (1) HCQ-IV: 12 rats received a single dose of 0.590 mg HCQ sulfate per animal via IV injection; (2) HCQ-IT: 20 rats received a single dose of 0.590 mg HCQ sulfate per animal via intratracheal (IT) administration; and (3) liposomal HCQ-IT: 20 rats received a single dose of 0.284 mg liposomal HCQ sulfate per animal via IT administration. The sampling time points for blood samples were 0.25, 1, 4, 24 and 72 hours post-dose and for tissue/organ samples were 0.25, 4, 24 and 72 hours post-dose. In this study, inhalable liposomal HCQ was administered through IT instillation to mimic the intended inhaled administration for the clinical setting. All procedures involving animals were performed in the TLC animal facility and in accordance with the ethical guidelines of Institutional Animal Care and Use Committee (IACUC) at TLC, Taiwan (#TLC20IACUC012).

Blood was collected from jugular veins with K₂EDTA as the anticoagulant and stored at -80°C. After blood draw, each animal was perfused with K₂EDTA/saline solution before lungs and hearts were collected and stored at -80°C.

Bioanalysis and PK calculation. The bioanalytical methods were developed according to the published method with modification. In brief, blood and tissue/organ samples were processed with acetonitrile with 0.1% formic acid for protein precipitation prior to analysis. The
concentrations of HCQ were determined by liquid chromatography (Waters ACQUITY UPLC-ICALSS)-tandem mass spectrometer (Water Xevo TQS; AB Sciex Triple Quad 5500) (LC-MS/MS). The linear range of three independent assays were 0.5-500 ng/mL, 0.5-500 ng/mL and 20-10,000 ng/mL for whole blood, heart and lung assay, respectively. PK parameters of HCQ were calculated by a non-compartmental method using Phoenix® WinNonlin® (version 8.0). PK parameters for tissue/organ were calculated using the sparse-sample option available in Phoenix® WinNonlin®.

**Statistical Analysis.** Two-sample $t$ tests were used to assess differences in concentration between liposomal HCQ-IT and HCQ-IV. $P < 0.05$ was considered significant.
Results

HCQ pharmacokinetics in lung. Upon IT administration of liposomal HCQ, there were significantly higher HCQ concentrations at 0.25 hours ($P < 0.001$), 4 hours ($P < 0.01$), 24 hours ($P < 0.001$) and 72 hours ($P < 0.01$) (Figure 1A) than with HCQ-IV and longer apparent half-life in lung compared to those of HCQ by either IV or IT administration (37.5 hours vs. 15.2 hours and 17.7 hours for HCQ-IV and HCQ-IT, respectively) (Table 1). A single dose of 0.284 mg liposomal HCQ-IT achieved $129.4 \, \mu g/g$ in $C_{\text{max}}$ and $4193.2 \, h*\mu g/g$ in $AUC_{0-72}$ and showed overall greater lung exposure with 29-fold in $C_{\text{max}}$ and 35-fold in $AUC_{0-72}$ compared to HCQ-IV with normalized dose.

HCQ pharmacokinetics in blood and heart. In contrast to lung, liposomal HCQ-IT showed significantly lower systemic exposure in blood at 0.25 hours ($P < 0.01$), 1 hours ($P < 0.001$) and 4 hours ($P < 0.05$) (Figure 1B) with only around 20% of $C_{\text{max}}$ and 74% of $AUC_{0-72}$ after normalizing dose compared to HCQ-IV. As observed in blood, liposomal HCQ-IT showed significantly lower concentrations in the heart from 0.25 hours ($P < 0.01$), 4 hours ($P < 0.05$) to 24 hours ($P < 0.05$) (Figure 1C) with only 23% of $C_{\text{max}}$ and 58% of $AUC_{0-24}$ with normalized dose compared to HCQ-IV.
Discussion
In this rat pharmacokinetics study, a significantly higher exposure of HCQ with sustained release profile in the lung was observed by targeted delivery of inhalable liposomal HCQ, suggesting a potential treatment delivery option for COVID-19 pulmonary disease. Fan et al. and others have suggested that significantly higher lung (intracellular) concentrations relative to the in vitro EC$_{50}$ would be required to achieve in vivo antiviral efficacy SARS-CoV-2 8, 9. Also, it has been proposed that the prediction of in vivo efficacy should be driven primarily by high lung HCQ concentrations for treatment of viral pneumonia instead of HCQ blood exposure 9. Due to the indication that current dosing for HCQ is unlikely to inhibit COVID-19 virus, FDA recently revoked the emergency use authorization (EUA) to use HCQ to treat COVID-19 in certain hospitalized patients, and WHO also suspended the HCQ arm of the COVID-19 Solidarity Trial. Here our findings supported the feasibility of alternative targeted delivery of HCQ to the lungs, achieving potentially efficacious antiviral levels while minimizing systemic exposure.

The aerosolized delivery of therapeutic drugs to the lower respiratory tract has been applied for the treatment of various lung infectious and inflammatory disorders. For example, aerosolized HCQ (AHCQ) was tested in clinical trials for asthma 12. Moreover, ARIKAYCE®, an inhalable liposomal amikacin has been approved to treat lung infections with *Mycobacterium avium complex* 13. As shown in this proof-of-concept study, the inhalable liposomal HCQ did increase exposure in the lung with extended residence time, while reducing systemic exposure and heart distribution, compared to systemically administered HCQ. Notably, the significantly increased lung exposure (at normalized dose) suggested a relatively lower dose regimen of inhalable liposomal HCQ than oral regimens of HCQ tablets with loading dose initiation 14 could be explored and evaluated as a potential alternative strategy for COVID-19 treatment in future...
clinical studies.

One of the well-known side effects of HCQ is cardiotoxicity, including abnormal heart rhythms such as QTc interval prolongation and ventricular tachycardia, a dangerously rapid heart rate.\(^\text{15}\).

While the comparable dose-normalized AUC\(_{0-72}\) in heart was observed for liposomal HCQ (IT) and HCQ (IV) in current study, there was no aberrant heart tissue observed grossly. Moreover, in a separate study with multiple-dose IT administration of liposomal HCQ (0.30 mg) for 7 consecutive days, there was no histopathological change observed in rat heart tissues by hematoxylin and eosin (H&E) staining (data not shown). The HCQ exposure in heart with inhalable liposomal HCQ is expected to be much lower than with the conventional oral HCQ regimen used in the current clinical setting, given that a much lower dose would be required through inhalation. Nonetheless, considering the known cardiotoxicity potential of HCQ, electrocardiogram (ECG) monitoring for cardiac safety assessment would be warranted in future clinical trials of inhalable liposomal HCQ.

While there is no commercially available aerosolized formulation of HCQ, a recent empirical study of inhaled HCQ aerosols at 4 mg per day over one week found it was well tolerated without significant adverse events.\(^\text{16}\) Further, AHCQ has been proposed to be delivered directly to the lungs for early treatment or prophylaxis of COVID at a lower dose (20 mg daily), which has been demonstrated to be well tolerated for up to 21 days of dosing.\(^\text{17}\) This further supports the rationale of applying inhalable liposomal HCQ with direct lung targeting in COVID-19 infection/disease prevention and treatment.

A limitation of the current study is that the pharmacokinetics of liposomal HCQ were evaluated in a rat model using IT instillation to mimic the intended inhalation administration. The typical lung deposition efficiency with inhaled aerosols is very likely lower than that of the IT instilled
microsprayed-droplets. Furthermore, aerosol-generating procedures such as nebulization should be performed cautiously in patients with known or suspected COVID-19 given that SARS-CoV-2 is highly contagious through the respiratory route. Therefore, we have developed a disposable closed-loop system connected to the nebulizer to maximize the targeted delivery of inhaled liposomal HCQ while minimize the spreading of aerosols and contamination of the air and environment (data not shown).

In conclusion, this study in a rat model demonstrated the desirable pharmacokinetics of inhalable liposomal HCQ in vivo. It supports the working hypothesis that inhalable liposomal HCQ might serve as a potential treatment option to deliver HCQ directly to lung for COVID-19 pulmonary disease with less frequent dosing and at a relatively lower dose.
Study Highlights

- What is the current knowledge on the topic?
  The current dosing regimen of oral hydroxychloroquine (HCQ) has shown limited benefit for COVID-19 patients. One probable reason could be the low HCQ concentrations in lung leading to insufficient antiviral activity against SARS-CoV-2. However, high doses of oral HCQ may raise safety concerns, including heart rhythm issues.

- What question did this study address?
  The current pre-clinical study in a rat model aimed to investigate if an inhalable liposomal HCQ formulation could serve as an alternative strategy for COVID-19 treatment by providing a more preferable pharmacokinetic profile in lung than unformulated HCQ.

- What does this study add to our knowledge?
  Here a proof-of-concept study demonstrated that a novel inhalable liposomal HCQ formulation could provide preferentially higher lung concentrations, reduced systemic exposure and lower heart distribution compared to unformulated HCQ in a rat model.

- How might this change clinical pharmacology or translational science?
  A novel inhalable liposomal HCQ formulation could serve as a promising targeted delivery strategy to prevent or treat COVID-19 disease by providing in vivo antiviral effect at a significantly lower and safer dose.
Acknowledgements

We thank Dr. George Spencer-Green and Dr. Carl Brown for their critical review and suggestions for the manuscript. We also thank Ting-Yu Cheng for formulation development, staff in Department of Pharmacokinetics, Taiwan Liposome Company for laboratory support, and staff in the Nonclinical Department, Taiwan Liposome Company for support with the animal model.

Author Contributions

References


Figure 1. Mean concentration (±SD) - time profiles of HCQ in rat lung (A), blood (B), and heart (C) after a single administration of HCQ through intravenous (IV) or intratracheal (IT) delivery or liposomal HCQ through IT delivery. The inset graph (B) showed mean concentration-time profiles of HCQ in 0.25 to 4 hours. *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$; ns$P > 0.05$ compared to HCQ-IV.
Table 1. Pharmacokinetic parameters of hydroxychloroquine in lung, blood, and heart after a single administration of liposomal hydroxychloroquine or hydroxychloroquine in rats.

<table>
<thead>
<tr>
<th>Pharmacokinetic Parameters</th>
<th>HCQ-IV (0.590 mg)</th>
<th>HCQ-IT (0.590 mg)</th>
<th>Liposomal HCQ-IT (0.284 mg)</th>
<th>Liposomal HCQ-IT to HCQ-IV (^b)</th>
<th>Liposomal HCQ-IT to HCQ-IT (^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lung</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( T_{\text{max}} ) (h)</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>( C_{\text{max}} ) (μg/g)</td>
<td>9.4</td>
<td>47.8</td>
<td>129.4</td>
<td>29</td>
<td>5.6</td>
</tr>
<tr>
<td>AUC(_{0-72} ) (h*μg/g)</td>
<td>251.6</td>
<td>328.6</td>
<td>4193.2</td>
<td>35</td>
<td>27</td>
</tr>
<tr>
<td>( t_{1/2} ) (h)</td>
<td>15.2</td>
<td>17.7</td>
<td>37.5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Blood</strong>(^c)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( T_{\text{max}} ) (h)</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>( C_{\text{max}} ) (ng/mL)</td>
<td>433.4 ± 63.6</td>
<td>476.7 ± 63.2</td>
<td>42.5 ± 18.5</td>
<td>0.20</td>
<td>0.19</td>
</tr>
<tr>
<td>AUC(_{0-72} ) (h*ng/mL)</td>
<td>2333.2 ± 247.6</td>
<td>2257.0 ± 420.7</td>
<td>827.6 ± 286.0</td>
<td>0.74</td>
<td>0.76</td>
</tr>
<tr>
<td>( t_{1/2} ) (h)</td>
<td>15.3 ± 2.1</td>
<td>22.1 ± 5.7</td>
<td>55.2 ± 13.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Heart</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This article is protected by copyright. All rights reserved
<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$T_{\text{max}}$ (h)</td>
<td>0.25</td>
<td>0.25</td>
<td>24</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>$C_{\text{max}}$ (μg/g)</td>
<td>4.5</td>
<td>3.8</td>
<td>0.5</td>
<td>0.23</td>
<td>0.27</td>
</tr>
<tr>
<td>$\text{AUC}_{0-24}$ (h*μg/g)</td>
<td>42.6</td>
<td>41.5</td>
<td>11.9</td>
<td>0.58</td>
<td>0.60</td>
</tr>
<tr>
<td>$\text{AUC}_{0-72}$ (h*μg/g)</td>
<td>67.2</td>
<td>64.2</td>
<td>32.1</td>
<td>0.99</td>
<td>1.04</td>
</tr>
</tbody>
</table>
HCQ, hydroxychloroquine; IV, intravenous; IT, intratracheal; $T_{\text{max}}$, time to reach maximum concentration; $C_{\text{max}}$, maximum concentration; AUC$_{0-72}$, area under the concentration-time curve from time zero to 72 hours;

AUC$_{0-24}$, area under the concentration-time curve from time zero to 24 hours; $t_{1/2}$, apparent elimination half-life.

$^a$ N=4 for blood sample at 1 hour time-point of liposomal HCQ-IT due to blood coagulation

$^b$ Data are presented as dose-normalized ratios.

$^c$ Data are presented as mean ± SD, except $T_{\text{max}}$ are presented as median.